INDIRECT COMPARISON OF LINVOSELTAMAB VERSUS TECLISTAMAB FOR TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hans Lee, 420066

OPERATIONAL CURE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANT AS FIRST-LINE THERAPY AND  IMPACT OF INDUCTION REGIMENS

EHA Library, Jose Miguel Mateos Perez, 420067

REAL-WORLD TREATMENT PATTERNS, EFFICACY, AND SAFETY OF DARATUMUMAB-BASED REGIMENS IN CHINESE PATIENTS WITH MULTIPLE MYELOMA: AN UPDATED ANALYSIS OF THE MMY4032 STUDY

EHA Library, Luqun Wang, 420068

A PHASE 2 STUDY OF ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RRMM PATIENTS WITH 1 PRIOR LINE OF THERAPY

EHA Library, Evangelos Terpos, 420069

A COMPARISON OF PATIENT-REPORTED PERIPHERAL NEUROPATHY AMONG PATIENTS TREATED WITH ELRANATAMAB VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA

EHA Library, Paula Rodríguez-Otero, 420070

CLINICAL CHARACTERISTICS AND PROGNOSTIC ANALYSIS OF NON-AMYLOID MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS) IN CHINA:  A LARGE-COHORT RETROSPECTIVE STUDY.

EHA Library, Yang Liu, 420071

LONGITUDINAL ASSESSMENT OF CONTEMPORARY RISK STRATIFICATION MODELS IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

EHA Library, Kosima Zuern, 420072

EFFICACY AND SAFETY OF IXAZOMIB-BASED SALVAGE THERAPIES IN MULTIPLE MYELOMA PATIENTS WITH A PRIOR HISTORY OF BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY

EHA Library, Xiang Zhou, 420073

EPIDEMIOLOGY AND REAL-WORLD MANAGEMENT OF MONOCLONAL GAMMOPATHIES PATIENTS IN SPAIN BASED ON NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING TECHNIQUES, THE CIMMA STUDY

EHA Library, Joaquín Martínez-López, 420074

TREATMENT GOALS AND DECISION-MAKING CRITERIA FOR SECOND- AND THIRD-LINE THERAPY FOR MULTIPLE MYELOMA IN GERMANY

EHA Library, H Tilman Steinmetz, 420075

HYPOALBUMINEMIA, A NEW RISK FACTOR FOR PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE?

EHA Library, Elena Alejo, 420076

OUTCOMES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND RENAL INVOLVEMENT: FINDINGS FROM THE TRINETX DATABASE

EHA Library, Richa Manwani, 420077

WHAT CAN WE TELL OUR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO PRESENT WITH SEVERE RENAL INSUFFICIENCY REQUIRING DIALYSIS ABOUT RENAL RECOVERY? A CANADIAN SINGLE-CENTRE ANALYSIS

EHA Library, Rintu Sharma, 420078

CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB -DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL-LIFE MULTI-CENTER RETROSPECTIVE EXPERIENCE

EHA Library, Danilo De Novellis, 420079

OUTCOMES WITH SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): REGIONAL SUBGROUP ANALYSIS OF THE PHASE 3 BOSTON TRIAL

EHA Library, Andrew Spencer, 420080

IGH GENE REARRANGEMENT PATTERNS OBSERVED WITH THE USE OF FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN MULTIPLE MYELOMA PATIENTS

EHA Library, Natalia Tsybakova, 420081

EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: CLINICOBIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT

EHA Library, Aleksandra Sretenovic, 420082

CONTINUOUS THERAPY IN HHV-8 NEGATIVE MULTICENTRIC CASTLEMAN DISEASE: PIONEERING PROLONGED PROGRESSION-FREE SURVIVAL

EHA Library, Liangshun You, 420083

SECONDARY RESISTANCE MECHANISMS AFTER BCMA-TARGETING THERAPIES IN MULTIPLE MYELOMA:  WHOLE-GENOME SEQUENCING AND IN SILICO STRUCTURAL MODELING IDENTIFIES NOVEL TNFRSF17 MUTATIONS

EHA Library, Ricardo Kosch, 420084

IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXAPD) PAN-ORAL REGIMEN IN THE TREATMENT OF REFRACTORY AND RELAPSED MULTIPLE MYELOMA

EHA Library, Miao Chen, 420085

PROGNOSTIC SIGNIFICANCE OF COMPOSITE HEMATOLOGIC AND ORGAN RESPONSE (CHOR) IN NEWLY DIAGNOSED PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS.

EHA Library, Marko Mitrovic, 420086

MINIMAL RESIDUAL DISEASE ASSESSMENT AND IMMUNE CORRELATES IN MULTIPLE MYELOMA THROUGH FLOW CYTOMETRY: A REAL-WORLD EXPERIENCE

EHA Library, Andrea Rizzuto, 420087

CARFIL-HAD PILOT STUDY: SECURE OUTSOURCING IN HOSPITALIZATION AT HOME (HAH) OF CARFILZOMIB IN MULTIPLE MYELOMA TREATMENT. CARE MODEL ORGANIZATION FOR SHORT-DURATION INTRAVENOUS CHEMOTHERAPIES AT HOME

EHA Library, Mohamed Touati, 420088

COMPARING CYTOGENETIC ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA BETWEEN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS USING CHROMOSOME MICROARRAY ANALYSIS

EHA Library, Matthew Hamby, 420089

USING SERUM PROTEOMICS TO IDENTIFY FRAIL PATIENTS WITH MYELOMA

EHA Library, John Burthem, 420090

EVALUATION OF FACTORS ASSOCIATED WITH PROGRESSION FROM SMOLDERING MULTIPLE MYELOMA TO ACTIVE MULTIPLE MYELOMA

EHA Library, Elvira Umyarova, 420091

ROLE OF RED CELL MASS EVALUATION IN MYELOPROLIFERATIVE NEOPLASMS WITH SPLANCHNIC VEIN THROMBOSIS AND NORMAL HEMOGLOBIN VALUE: A STUDY OF THE FRANCE INTERGROUPE DES SYNDROMES MYELOPROLIFÉRATIFS.

EHA Library, Jean Galtier, 420092

CLINICAL, HISTOPATHOLOGIC, AND ARTIFICIAL INTELLIGENCE (AI) EVALUATION OF MYELOPROLIFERATIVE NEOPLASM (MPN) DIAGNOSIS IN PATIENTS WITH MPN RELATED SPLANCHNIC VEIN THROMBOSIS (SVT)

EHA Library, Bharath Ram Sreedhar, 420093

COMPREHENSIVE ANALYSIS OF DIAGNOSIS, TREATMENT AND OUTCOME IN A RETROSPECTIVE COHORT OF HES PATIENTS IN THE SOUTH-WEST OF THE NETHERLANDS BETWEEN 2000-2020.

EHA Library, Pim Mutsaers, 420094

PATIENT JOURNEY TO DIAGNOSIS AND TREATMENT OF HYPEREOSINOPHILIC SYNDROME IN EUROPE AND THE UNITED STATES: EVIDENCE FROM A REAL-WORLD SURVEY IN CLINICAL PRACTICE

EHA Library, Priya Jain, 420095

MOMELOTINIB MANAGED ACCESS PROGRAM FOR PATIENTS WITH MYELOFIBROSIS: BASELINE CHARACTERISTICS IN THE UK, ITALY, GREECE, AUSTRIA, AND BELGIUM

EHA Library, Claire Harrison, 420096

RUXOLITINIB IMPROVED SURVIVAL IN MYELOFIBROSIS PATIENTS WITH 1 OR MORE HIGH MOLECULAR RISK  MUTATIONS

EHA Library, Chun Teh, 420097

ACCELERATED IMMUNE EFFECTOR CELL RECONSTITUTION IN MYELOFIBROSIS PATIENTS TREATED WITH MOMELOTINIB AFTER RUXOLITINIB

EHA Library, Jasmine Makker, 420098

EXPLORING PERCEPTIONS IN MANAGEMENT AND TREATMENT OF POLYCYTHAEMIA VERA (PV) IN THE UK: PV-PINPOINT STUDY

EHA Library, Mary Frances McMullin, 420099

SEVERE ANEMIA AND CO-OCCURRENCE OF ANEMIA AND THROMBOCYTOPENIA IDENTIFY VERY HIGH-RISK PMF PATIENTS

EHA Library, Paola Guglielmelli, 420100

IMPACT OF ATRIAL FIBRILLATION ON THROMBOTIC COMPLICATIONS IN MPN PH-NEG PATIENTS: REAL-LIFE ANALYSIS

EHA Library, Olga Chyrko, 420101

MITIGATION OF ATRIAL FIBRILLATION-RELATED COMPLICATIONS WITH  COMBINED ANTITHROMBOTIC AND CYTOREDUCTIVE THERAPY IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Hyunyee Rosa Cho, 420102

LONG-TERM OUTCOME AND PROGNOSIS OF 69 PATIENTS WITH MIXED HISTIOCYTOSIS

EHA Library, Francesco Pegoraro, 420103

RELATIONSHIP BETWEEN THE KITD816V ALLELE BURDEN AND MEDIATOR-RELATED SYMPTOMS EVALUATED WITH THE INDOLENT SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ISM-SAF)

EHA Library, Chiara Sartor, 420104

HYPOMETHYLATING AGENTS ARE EFFECTIVE IN TREATMENT FOR RELAPSED MYELOFIBROSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Haris Ali, 420105

EASIX SCORE INDICATIVE OF ENDOTHELIAL DYSFUNCTION IS ASSOCIATED WITH HIGHER THROMBOTIC RISK AND IMPAIRED SURVIVAL IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Marko Lucijanic, 420106

PROGNOSTIC POTENTIAL OF INFLAMMATORY BIOMARKERS IN PATIENTS WITH POLYCYTHEMIA VERA RECEIVING RUXOLITINIB: AN EXPLORATORY ANALYSIS OF RESPONSE, RESPONSE-2, AND PV-NIS

EHA Library, Francesca Palandri, 420107

ASSOCIATION BETWEEN HEMOGLOBIN IMPROVEMENT AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: POST HOC POOLED ANALYSIS OF MOMELOTINIB PHASE 3 TRIALS

EHA Library, Jeanne Palmer, 420108

HYPEREOSINOPHILIC DISORDERS: PRELIMINARY REAL-WORLD ANALYSIS BY PH-NEGATIVE MPN LATIAL GROUP

EHA Library, Caterina Tatarelli, 420109

CAUSE-SPECIFIC MORTALITY TRENDS IN MYELOPROLIFERATIVE NEOPLASMS ACROSS DEMOGRAPHIC GROUPS: A RETROSPECTIVE COHORT STUDY

EHA Library, Muhammad Ali Khan, 420110

PROGNOSTIC NUTRITIONAL INDEX (PNI) AT DIAGNOSIS PREDICTS OUTCOME IN PATIENTS WITH PRIMARY MYELOFIBROSIS: A MONOCENTRIC REAL-LIFE STUDY

EHA Library, Veronica Guglielmana, 420111

EVALUATING MOLECULAR RISK FACTORS AND MUTATIONAL MODELS IN MYELOFIBROSIS AT A MULTI-ETHNIC INNER-CITY CENTER

EHA Library, John Yan, 420113

COMPARING THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH LOWER AND HIGHER RISK MYELOFIBROSIS: A SINGLE-ARM, EXPLORATORY AND PROSPECTIVE STUDY

EHA Library, JIAN HUANG, 420114

MYMPNVOICE – THE NEW MPN APP FOR PATIENT REPORTED OUTCOMES AND BIOMETRIC DATA MONITORING

EHA Library, Patrick Harrington, 420115

THE CLINICAL BURDEN OF MYELOFIBROSIS AND ASSOCIATED ANEMIA IN FRANCE

EHA Library, Alexander Slowley, 420116

VARIABLES ASSOCIATED WITH OUTCOMES IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASM IN ACCELERATED PHASE/BLAST PHASE

EHA Library, Jiang Qian, 420117

EVALUATION OF THE RISKS OF DEVELOPING SECONDARY CANCERS IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Maria Jana Kingsley-Godwin, 420118

A RETROSPECTIVE ANALYSIS OF PACRITINIB TREATMENT OUTCOMES IN MYELOFIBROSIS PATIENTS WITH AND WITHOUT MONOCYTOSIS

EHA Library, John Mascarenhas, 420119

HEALTH-RELATED QUALITY OF LIFE IN ITALIAN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPARED TO THE GENERAL POPULATION: GIMEMA PROPHECY STUDY

EHA Library, Giovanni Caocci, 420120

PROSPECTIVE REAL-WORLD EVIDENCE OF BRENTUXIMAB VEDOTIN (BV) CONSOLIDATION AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RR HL)

EHA Library, Astrid Pavlovsky, 420121

ANTI-TIM-3 ANTIBODY TQB2618 IN COMBINATION WITH PENPULIMAB IN RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH PD-1/PD-L1 THERAPY

EHA Library, Tongyu Lin, 420122

BCL-2-POSITIVE TUMOUR CELLS AS PREDICTORS OF THE COURSE OF NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA

EHA Library, Dmitry Diakonov, 420123

A MODIFIED EORTC H10 (MH10)-BASED APPROACH IN PATIENTS WITH LIMITED-STAGE CLASSICAL HODGKIN LYMPHOMA (LS-CHL): SINGLE CENTER 6-YEAR EXPERIENCE WITH FOCUS TO YOUNGER PATIENTS

EHA Library, Theodoros Vassilakopoulos, 420124

PREDICTIVE FACTORS OF AUTOLOGOUS STEM CELL TRANSPLANTATION OUTCOMES AFTER ANTI-PD-1 TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Nikita Mochkin, 420125

COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB IN RELAPSED/REFRACTORY CHL AND PMBCL: AN ANALYSIS OF COHORTS A AND B OF THE KEYVIBE-004 STUDY

EHA Library, David Lavie, 420126

SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF KT-333, A TARGETED PROTEIN DEGRADER OF STAT3, IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC AND SOLID TUMOR CANCERS

EHA Library, Aditi Shastri, 420127

BRENTUXIMAB VEDOTIN AND BENDAMUSTINE FOR RELAPSED HODGKIN LYMPHOMA: HIGH CMR RATE AND MANAGEABLE TOXICITY

EHA Library, Zin Aung Soe, 420128

BRENTUXIMAB VEDOTIN IN COMBINATION WITH BEGEV IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA: 3-YEAR FOLLOW-UP.

EHA Library, Matvey Bulusov, 420129

CHANGES IN SURVIVAL OF PATIENTS WITH HODGKIN'S LYMPHOMA OVER THE LAST FOUR DECADES

EHA Library, Zsófia Miltényi, 420130

ODRONEXTAMAB MONOTHERAPY FOR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): CLINICAL PHARMACOLOGY AND PHARMACOMETRICS IN THE ELM-1 AND ELM-2 STUDIES

EHA Library, Raul Cordoba, 420131

REAL-WORLD ADHERENCE AND HEALTHCARE RESOURCE UTILIZATION OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN MANTLE CELL LYMPHOMA

EHA Library, Bijal D. Shah, 420132

HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A RETROSPECTIVE, SINGLE-CENTER ANALYSIS

EHA Library, Silvia Ferrari, 420133

MINIMAL RESIDUAL DISEASE MONITORING IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULT FROM FL-015 TRIAL.

EHA Library, Anna Smolyaninova, 420134

SIGNIFICANCE STUDY OF PET/CT IMAGING EVALUATION IN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA

EHA Library, Qingyang Zhang, 420135

THE RESULTS OF FRONTLINE INDUCTION IMMUNOCHEMOTHERAPY WITH R-GEMOX IN MANTLE CELL LYMPHOMA: A GOOD BALANCE BETWEEN EFFICACY AND SAFETY

EHA Library, Antonio Gutiérrez, 420136

RETROSPECTIVE ANALYSIS OF INFECTIOUS EVENTS IN LYMPHOMA PATIENTS WHO WERE TREATED WITH BENDAMUSTINE PLUS ANTI-CD20 MONOCLONAL ANTIBODY: KOREAN, MULTICENTER STUDY

EHA Library, Jun Ho Yi, 420137

THE CLINICAL CHARACTERISTICS AND PROGNOSIS OF FOLLICULAR LYMPHOMA GRADE 3A

EHA Library, Wenjuan Yu, 420138

FACTORS OF FAILURE OF THE MAIN 1ST-LINE IMMUNOCHEMOTHERAPY REGIMENS IN PATIENTS WITH FOLLICULAR LYMPHOMA: DATA FROM A TWO-CENTER STUDY

EHA Library, Evgenii Kunevich, 420139

REAL WORLD SAFETY AND EFFICACY DATA FOR USE OF RITUXIMAB AND BENDAMUSTINE (BR) IN TREATMENT OF ELDERLY AND OR UNFIT PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Sujeet Kumar, 420140

RESULTS FROM A PHASE 1 DOSE ESCALATION STUDY OF HMPL-760, A THIRD GENERATION, HIGHLY SELECTIVE, REVERSIBLE BTK INHIBITOR IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY (R/R) LYMPHOMAS

EHA Library, Ying Qian, 420141

LONG-TERM SURVIVAL OUTCOMES OF 'WATCH AND WAIT' IN PATIENTS WITH BRONCHUS-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: A MULTICENTER REAL-WORLD DATA ANALYSIS IN KOREA

EHA Library, Kunye Kwak, 420142

OBINUTUZUMAB (G) AND CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF FOLLICULAR LYMPHOMA GRADE IIIB (FL GR.3B) OR COMPOSITE FOLLICULAR AND B-LARGE CELL LYMPHOMA (FL/B-LCL)

EHA Library, Neno Živković, 420143

«LONG-TERM RESULTS OF THERAPY FOR PATIENTS WITH MANTLE CELL LYMPHOMA ACCORDING TO THE “MCL-2016” STUDY»

EHA Library, Evgeniy Zvonkov, 420144

INDIRECT COMPARISON OF EFFICACY OF ZANUBRUTINIB VERSUS ACALABRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

EHA Library, Bijal D. Shah, 420145

MINIMAL RESIDUAL DISEASE (MRD), PHARMACOKINETIC (PK), AND PHARMACODYNAMIC (PD) ASSESSMENT OF EPCORITAMAB 2- VS 3-STEP STEP-UP DOSING IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

EHA Library, Christopher Morehouse, 420146

MODEL-BASED CYCLE (C) 1 OPTIMIZATION OF STEP-UP DOSE REGIMEN FOR EPCORITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

EHA Library, Kinjal Sanghavi, 420147

TREATMENT OUTCOMES OF BLASTOID-VARIANT MANTLE CELL LYMPHOMA. AN IRISH RETROSPECTIVE MULTI-CENTRE STUDY.

EHA Library, Alfred Jones, 420148

SIMILAR SAFETY PROFILE FOR RITUXIMAB AND OBINUTUZUMAB AS MAINTENANCE FOR FOLLICULAR LYMPHOMA: EVIDENCE FROM A REAL-WORLD MULTICENTER RETROSPECTIVE COHORT STUDY

EHA Library, Ronit Gurion, 420149

THE NUMBER OF CHROMOSOMAL ABERRATIONS IMPACTS SURVIVAL OUTCOMES IN WALDENSTRÖM MACROGLOBULINEMIA: EXPERIENCE FROM A TERTIARY ACADEMIC CENTER

EHA Library, Nicolò Danesin, 420150

CHARACTERIZATION OF WALDENSTRÖM MACROGLOBULINEMIA WITH A FOCUS ON UNUSUAL IMMUNOPHENOTYPES: DIAGNOSTIC CLUES AND POTENTIAL BIOLOGICAL UNDERPINNINGS

EHA Library, Nicolò Danesin, 420151

PROGNOSTIC IMPACT OF GENDER IN NEWLY DIAGNOSED MCL IS ASSOCIATED WITH HIGHER PREVALENCE OF ADVERSE GENETIC EVENTS IN MALES COMPARED TO FEMALES

EHA Library, Diana Malarikova, 420152

FAVEZELIMAB (ANTI-LAG-3) PLUS PEMBROLIZUMAB (PEMBRO) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA: COHORT 4 OF A MULTICOHORT OPEN-LABEL PHASE 1/2 STUDY

EHA Library, David Lavie, 420153

CLINICAL MANIFESTATIONS OF 35 NK CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

EHA Library, Zhe Zhuang, 420154

IMPACT OF EARLY RELAPSE (POD24) & P53 ALTERATIONS ON TREATMENT OUTCOMES IN PATIENTS WITH MCL, MULTI-CENTRE, RETROSPECTIVE COHORT STUDY IN IRELAND.

EHA Library, Ezzat Elhassadi, 420155

THE SAFETY AND EFFICACY OF OBINUTUZUMAB PLUS CHEMOTHERAPY THERAPY FOR UNTREATED FOLLICULAR LYMPHOMA: A CHINESE RETROSPECTIVE ANALYSIS

EHA Library, Zheng Song, 420156

DOSE ADJUSTMENT OUTCOMES IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

EHA Library, Shayna Sarosiek, 420157

THE EFFICACY AND SAFETY OF OBINUTUZUMAB WITH ZANUBRUTINIB AS FIRST-LINE TREATMENT IN OLDER PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Yanan Zhu, 420158

IMPACT OF VACCINATION AND CURRENT IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA PATIENTS WITH COVID-19

EHA Library, Mengyuan He, 420159

EVALUATION OF ANEMIA IN NEWLY DIAGNOSED PATIENTS WITH MALIGNANT LYMPHOMAS

EHA Library, Nina Petkova, 420160

ORELABRUTINIB IN PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL) INTOLERANT TO PRIOR BRUTON TYROSINE KINASE INHIBITORS (BTKI): PRELIMINARY RESULTS FROM A PHASE 2 STUDY

EHA Library, Li Wang, 420161

GLOFITAMAB MONOTHERAPY RETREATMENT IN PATIENTS WITH HEAVILY PRETREATED RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: RESULTS FROM A PHASE I/II STUDY

EHA Library, Emmanuel Bachy, 420162

POLATUZUMAB VEDOTIN, ZANUBRUTINIB AND RITUXIMAB (POLA-ZR) ACHIEVED RAPID AND DEEP RESPONSE IN PREVIOUSLY UNTREATED FRAIL AND ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: UPDATED FOLLOW-UP

EHA Library, Yuhong Ren, 420163

OUTCOMES OF PATIENTS WITH PRIMARY CNS LYMPHOMA TREATED WITH MATRIX CHEMOIMMUNOTHERAPY FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT – A MULTICENTRE, RETROSPECTIVE STUDY

EHA Library, Adam Suleman, 420164

SIX VS. EIGHT DOSES OF RITUXIMAB IN COMBINATION WITH SIX CYCLES OF CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

EHA Library, Yoshimasa Kamoda, 420165

CLINICAL AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH DOUBLE/TRIPLE HIT DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Yi-ge Shen, 420166